Cytek Biosciences Inc

CTKB is entrenched in a Stage 4 decline with a dominant downtrend across horizons, trading below key moving averages and pressured by a primary Support Failure pattern reinforcing bearish bias. Short-term momentum remains sideways with no oversold signals, and EMAs are acting as resistance. Execution favors selling into any rallies now.

• ↑Q1 revenue up 6% YoY to $44.1 M, driven by service growth.
• ↑Service revenue grew 15% YoY to $15.4 M, boosting recurring income.
• ↓Net loss widened to $18.9 M vs. $11.4 M prior year, pressuring margins.